Suppr超能文献

用于慢性疼痛的非侵入性脑刺激技术

Non-invasive brain stimulation techniques for chronic pain.

作者信息

O'Connell Neil E, Marston Louise, Spencer Sally, DeSouza Lorraine H, Wand Benedict M

机构信息

Department of Clinical Sciences/Health Economics Research Group, Institute of Environment, Health and Societies, Brunel University, Kingston Lane, Uxbridge, Middlesex, UK, UB8 3PH.

出版信息

Cochrane Database Syst Rev. 2018 Apr 13;4(4):CD008208. doi: 10.1002/14651858.CD008208.pub5.

Abstract

BACKGROUND

This is an updated version of the original Cochrane Review published in 2010, Issue 9, and last updated in 2014, Issue 4. Non-invasive brain stimulation techniques aim to induce an electrical stimulation of the brain in an attempt to reduce chronic pain by directly altering brain activity. They include repetitive transcranial magnetic stimulation (rTMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), transcranial random noise stimulation (tRNS) and reduced impedance non-invasive cortical electrostimulation (RINCE).

OBJECTIVES

To evaluate the efficacy of non-invasive cortical stimulation techniques in the treatment of chronic pain.

SEARCH METHODS

For this update we searched CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, LILACS and clinical trials registers from July 2013 to October 2017.

SELECTION CRITERIA

Randomised and quasi-randomised studies of rTMS, CES, tDCS, RINCE and tRNS if they employed a sham stimulation control group, recruited patients over the age of 18 years with pain of three months' duration or more, and measured pain as an outcome. Outcomes of interest were pain intensity measured using visual analogue scales or numerical rating scales, disability, quality of life and adverse events.

DATA COLLECTION AND ANALYSIS

Two review authors independently extracted and verified data. Where possible we entered data into meta-analyses, excluding studies judged as high risk of bias. We used the GRADE system to assess the quality of evidence for core comparisons, and created three 'Summary of findings' tables.

MAIN RESULTS

We included an additional 38 trials (involving 1225 randomised participants) in this update, making a total of 94 trials in the review (involving 2983 randomised participants). This update included a total of 42 rTMS studies, 11 CES, 36 tDCS, two RINCE and two tRNS. One study evaluated both rTMS and tDCS. We judged only four studies as low risk of bias across all key criteria. Using the GRADE criteria we judged the quality of evidence for each outcome, and for all comparisons as low or very low; in large part this was due to issues of blinding and of precision.rTMSMeta-analysis of rTMS studies versus sham for pain intensity at short-term follow-up (0 to < 1 week postintervention), (27 studies, involving 655 participants), demonstrated a small effect with heterogeneity (standardised mean difference (SMD) -0.22, 95% confidence interval (CI) -0.29 to -0.16, low-quality evidence). This equates to a 7% (95% CI 5% to 9%) reduction in pain, or a 0.40 (95% CI 0.53 to 0.32) point reduction on a 0 to 10 pain intensity scale, which does not meet the minimum clinically important difference threshold of 15% or greater. Pre-specified subgroup analyses did not find a difference between low-frequency stimulation (low-quality evidence) and rTMS applied to the prefrontal cortex compared to sham for reducing pain intensity at short-term follow-up (very low-quality evidence). High-frequency stimulation of the motor cortex in single-dose studies was associated with a small short-term reduction in pain intensity at short-term follow-up (low-quality evidence, pooled n = 249, SMD -0.38 95% CI -0.49 to -0.27). This equates to a 12% (95% CI 9% to 16%) reduction in pain, or a 0.77 (95% CI 0.55 to 0.99) point change on a 0 to 10 pain intensity scale, which does not achieve the minimum clinically important difference threshold of 15% or greater. The results from multiple-dose studies were heterogeneous and there was no evidence of an effect in this subgroup (very low-quality evidence). We did not find evidence that rTMS improved disability. Meta-analysis of studies of rTMS versus sham for quality of life (measured using the Fibromyalgia Impact Questionnaire (FIQ) at short-term follow-up demonstrated a positive effect (MD -10.80 95% CI -15.04 to -6.55, low-quality evidence).CESFor CES (five studies, 270 participants) we found no evidence of a difference between active stimulation and sham (SMD -0.24, 95% CI -0.48 to 0.01, low-quality evidence) for pain intensity. We found no evidence relating to the effectiveness of CES on disability. One study (36 participants) of CES versus sham for quality of life (measured using the FIQ) at short-term follow-up demonstrated a positive effect (MD -25.05 95% CI -37.82 to -12.28, very low-quality evidence).tDCSAnalysis of tDCS studies (27 studies, 747 participants) showed heterogeneity and a difference between active and sham stimulation (SMD -0.43 95% CI -0.63 to -0.22, very low-quality evidence) for pain intensity. This equates to a reduction of 0.82 (95% CI 0.42 to 1.2) points, or a percentage change of 17% (95% CI 9% to 25%) of the control group outcome. This point estimate meets our threshold for a minimum clinically important difference, though the lower confidence interval is substantially below that threshold. We found evidence of small study bias in the tDCS analyses. We did not find evidence that tDCS improved disability. Meta-analysis of studies of tDCS versus sham for quality of life (measured using different scales across studies) at short-term follow-up demonstrated a positive effect (SMD 0.66 95% CI 0.21 to 1.11, low-quality evidence).Adverse eventsAll forms of non-invasive brain stimulation and sham stimulation appear to be frequently associated with minor or transient side effects and there were two reported incidences of seizure, both related to the active rTMS intervention in the included studies. However many studies did not adequately report adverse events.

AUTHORS' CONCLUSIONS: There is very low-quality evidence that single doses of high-frequency rTMS of the motor cortex and tDCS may have short-term effects on chronic pain and quality of life but multiple sources of bias exist that may have influenced the observed effects. We did not find evidence that low-frequency rTMS, rTMS applied to the dorsolateral prefrontal cortex and CES are effective for reducing pain intensity in chronic pain. The broad conclusions of this review have not changed substantially for this update. There remains a need for substantially larger, rigorously designed studies, particularly of longer courses of stimulation. Future evidence may substantially impact upon the presented results.

摘要

背景

这是2010年第9期发表的原始Cochrane系统评价的更新版本,上次更新于2014年第4期。非侵入性脑刺激技术旨在通过直接改变脑活动来诱导对大脑的电刺激,以减轻慢性疼痛。它们包括重复经颅磁刺激(rTMS)、颅部电刺激疗法(CES)、经颅直流电刺激(tDCS)、经颅随机噪声刺激(tRNS)和低阻抗非侵入性皮层电刺激(RINCE)。

目的

评估非侵入性皮层刺激技术治疗慢性疼痛的疗效。

检索方法

本次更新,我们检索了Cochrane系统评价数据库、MEDLINE、Embase、护理学与健康领域数据库、心理学文摘数据库、拉丁美洲及加勒比地区卫生科学数据库以及临床试验注册库,检索时间为2013年7月至2017年10月。

入选标准

rTMS、CES、tDCS、RINCE和tRNS的随机及半随机研究,需设置假刺激对照组,纳入年龄在18岁以上、疼痛持续3个月及以上的患者,并将疼痛作为一项结局指标进行测量。感兴趣的结局指标包括使用视觉模拟量表或数字评定量表测量的疼痛强度、残疾情况、生活质量及不良事件。

数据收集与分析

两名综述作者独立提取并核实数据。在可能的情况下,我们将数据纳入Meta分析,排除被判定为高偏倚风险的研究。我们使用GRADE系统评估核心比较的证据质量,并创建了三个“结果总结”表。

主要结果

本次更新纳入了另外38项试验(涉及1225名随机分组参与者),使本综述共纳入94项试验(涉及2983名随机分组参与者)。本次更新共纳入42项rTMS研究、11项CES研究、36项tDCS研究、2项RINCE研究和2项tRNS研究。一项研究同时评估了rTMS和tDCS。在所有关键标准方面,我们仅判定4项研究为低偏倚风险。使用GRADE标准,我们判定每个结局指标以及所有比较的证据质量为低或极低;在很大程度上,这是由于盲法和精确性问题所致。

rTMS:rTMS研究与假刺激在短期随访(干预后0至<1周)时疼痛强度的Meta分析(27项研究,涉及655名参与者)显示有小的效应且存在异质性(标准化均数差(SMD)-0.22,95%置信区间(CI)-0.29至-0.16,低质量证据)。这相当于疼痛减轻7%(95%CI 5%至9%),或在0至10分的疼痛强度量表上降低0.40分(95%CI 0.53至0.32),未达到最小临床重要差异阈值15%或更高。预先设定的亚组分析未发现低频刺激(低质量证据)与应用于前额叶皮层的rTMS相比,在短期随访时减轻疼痛强度方面与假刺激存在差异(极低质量证据)。单剂量研究中对运动皮层的高频刺激与短期随访时疼痛强度的小幅度短期降低相关(低质量证据,汇总n = 249,SMD -0.38,95%CI -0.49至-0.27)。这相当于疼痛减轻12%(95%CI 9%至16%),或在0至10分的疼痛强度量表上变化0.77分(95%CI 0.55至0.99),未达到最小临床重要差异阈值15%或更高。多剂量研究的结果存在异质性,且在该亚组中未发现有效果的证据(极低质量证据)。我们未发现rTMS改善残疾情况的证据。rTMS与假刺激在短期随访时生活质量(使用纤维肌痛影响问卷(FIQ)测量)的研究Meta分析显示有积极效应(MD -10.80,95%CI -15.04至-6.55,低质量证据)。

CES

对于CES(5项研究,270名参与者),我们未发现主动刺激与假刺激在疼痛强度方面存在差异的证据(SMD -0.24,95%CI -0.48至0.01,低质量证据)。我们未发现CES对残疾有效性的相关证据。一项CES与假刺激在短期随访时生活质量(使用FIQ测量)的研究(36名参与者)显示有积极效应(MD -25.05,95%CI -37.82至-12.28,极低质量证据)。

tDCS:tDCS研究分析(27项研究,747名参与者)显示存在异质性,且主动刺激与假刺激在疼痛强度方面存在差异(SMD -0.43,95%CI -0.63至-0.22,极低质量证据)。这相当于降低0.82分(95%CI 0.42至1.2),或相对于对照组结局的百分比变化为17%(95%CI 9%至25%)。尽管较低的置信区间远低于该阈值,但该点估计值达到了我们的最小临床重要差异阈值。我们在tDCS分析中发现了小研究偏倚的证据。我们未发现tDCS改善残疾情况的证据。tDCS与假刺激在短期随访时生活质量(各研究使用不同量表测量)的研究Meta分析显示有积极效应(SMD 0.66,95%CI 0.21至1.11,低质量证据)。

不良事件

所有形式的非侵入性脑刺激和假刺激似乎都经常与轻微或短暂的副作用相关,在纳入研究中报告了2例癫痫发作,均与主动rTMS干预有关。然而,许多研究未充分报告不良事件。

作者结论

有极低质量的证据表明,单剂量的运动皮层高频rTMS和tDCS可能对慢性疼痛和生活质量有短期影响,但存在多种可能影响观察到的效应的偏倚来源。我们未发现低频rTMS、应用于背外侧前额叶皮层的rTMS和CES对减轻慢性疼痛强度有效的证据。本次更新中,本综述的广泛结论没有实质性变化。仍然需要开展规模更大、设计更严谨的研究,尤其是更长疗程刺激的研究。未来的证据可能会对呈现的结果产生重大影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc2/6494527/36654b6621a7/nCD008208-AFig-FIG01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验